Zai Lab to present Phase 1 trial data on DLL3-targeting ADC ZL-1310 at AACR 2026

Reuters

Mar 18

<a href="https://laohu8.com/S/ZAILF">Zai Lab</a> to present Phase 1 trial data on DLL3-targeting ADC ZL-1310 at AACR 2026

Zai Lab said it will present new data on three internally developed oncology candidates across four poster sessions at the AACR Annual Meeting 2026 in San Diego, scheduled for April 17-22. Two phase 1 clinical trial posters on the DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan (ZL-1310) are scheduled for April 21, including an analysis of intracranial activity in previously treated extensive-stage small cell lung cancer patients with baseline brain metastasis and preliminary results from a phase 1b/2 study in neuroendocrine carcinomas and selected solid tumors. A discovery poster on ZL-6201, an LRRC15-targeting antibody-drug conjugate being evaluated for sarcomas and epithelial solid tumors, is scheduled for April 20. A preclinical poster on ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, is scheduled for April 21.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260317815099) on March 17, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2620403573"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620403573\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620403573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 04:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620403573","market":"fut","top_or_hot":-1,"title":"Zai Lab to present Phase 1 trial data on DLL3-targeting ADC ZL-1310 at AACR 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZAILF\">Zai Lab</a> to present Phase 1 trial data on DLL3-targeting ADC ZL-1310 at AACR 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ZLAB\">Zai Lab</a> said it will present new data on three internally developed oncology candidates across four poster sessions at the AACR Annual Meeting 2026 in San Diego, scheduled for April 17-22. Two phase 1 clinical trial posters on the DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan (ZL-1310) are scheduled for April 21, including an analysis of intracranial activity in previously treated extensive-stage small cell lung cancer patients with baseline brain metastasis and preliminary results from a phase 1b/2 study in neuroendocrine carcinomas and selected solid tumors. A discovery poster on ZL-6201, an LRRC15-targeting antibody-drug conjugate being evaluated for sarcomas and epithelial solid tumors, is scheduled for April 20. A preclinical poster on ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, is scheduled for April 21.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260317815099) on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zai Lab to present Phase 1 trial data on DLL3-targeting ADC ZL-1310 at AACR 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZai Lab to present Phase 1 trial data on DLL3-targeting ADC ZL-1310 at AACR 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 04:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZAILF\">Zai Lab</a> to present Phase 1 trial data on DLL3-targeting ADC ZL-1310 at AACR 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ZLAB\">Zai Lab</a> said it will present new data on three internally developed oncology candidates across four poster sessions at the AACR Annual Meeting 2026 in San Diego, scheduled for April 17-22. Two phase 1 clinical trial posters on the DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan (ZL-1310) are scheduled for April 21, including an analysis of intracranial activity in previously treated extensive-stage small cell lung cancer patients with baseline brain metastasis and preliminary results from a phase 1b/2 study in neuroendocrine carcinomas and selected solid tumors. A discovery poster on ZL-6201, an LRRC15-targeting antibody-drug conjugate being evaluated for sarcomas and epithelial solid tumors, is scheduled for April 20. A preclinical poster on ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, is scheduled for April 21.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260317815099) on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL7jsWGv:1","article_id":"2620403573","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620403573","pubTimestamp":1773779722,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zai Lab said it will present new data on three internally developed oncology candidates across four poster sessions at the AACR Annual Meeting 2026 in San Diego, scheduled for April 17-22. Two phase 1 clinical trial posters on the DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan  are scheduled for April 21, including an analysis of intracranial activity in previously treated extensive-stage small cell lung cancer patients with baseline brain metastasis and preliminary results from a phase 1b/2 study in neuroendocrine carcinomas and selected solid tumors. A discovery poster on ZL-6201, an LRRC15-targeting antibody-drug conjugate being evaluated for sarcomas and epithelial solid tumors, is scheduled for April 20. A preclinical poster on ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, is scheduled for April 21.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1588":"回港中概股","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"再鼎医药将在AACR 2026上展示DLL3靶向ADC ZL-1310的1期试验数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":0.9},"content_text":"Zai Lab to present Phase 1 trial data on DLL3-targeting ADC ZL-1310 at AACR 2026\n    \n\nZai Lab said it will present new data on three internally developed oncology candidates across four poster sessions at the AACR Annual Meeting 2026 in San Diego, scheduled for April 17-22. Two phase 1 clinical trial posters on the DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan (ZL-1310) are scheduled for April 21, including an analysis of intracranial activity in previously treated extensive-stage small cell lung cancer patients with baseline brain metastasis and preliminary results from a phase 1b/2 study in neuroendocrine carcinomas and selected solid tumors. A discovery poster on ZL-6201, an LRRC15-targeting antibody-drug conjugate being evaluated for sarcomas and epithelial solid tumors, is scheduled for April 20. A preclinical poster on ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, is scheduled for April 21.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260317815099) on March 17, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}